^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avzivi (bevacizumab-tnjn)

    i
    Other names: BAT1706
    Company:
    BeiGene, Bio-Thera Solutions, Biomm, Cipla, Mega Lifesciences, Sandoz
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    4d
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    4d
    ZIABC011078: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    7d
    APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | N=40 --> 60 | Trial completion date: Apr 2027 --> Dec 2025 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    12d
    Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=127, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    Avastin (bevacizumab) • paclitaxel • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • tolinapant (ASTX660)
    1m
    Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov)
    P3, N=3610, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    MSI (Microsatellite instability) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • fluorouracil topical
    1m
    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=349, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Metastases
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Torisel (temsirolimus) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Ixempra (ixabepilone) • patupilone (EPO 906)
    2ms
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov)
    P3, N=50, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=454, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov)
    P3; N=4994; Active, not recruiting; Sponsor:National Cancer Institute (NCI)
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    CELLSEARCH®
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery • Metastases
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • etoposide IV • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=403, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • docetaxel • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • fluorouracil topical
    2ms
    SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov)
    P3, N=427, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Metastases
    |
    Avastin (bevacizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Intron A (interferon α-2b) • octreotide acetate
    2ms
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=94, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    3ms
    Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma (clinicaltrials.gov)
    P2/3, N=101, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    Avastin (bevacizumab) • temozolomide • Zolinza (vorinostat) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    4ms
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=169, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Jan 2025
    Trial completion date • Surgery • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    5ms
    Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov)
    P3, N=3610, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    MSI (Microsatellite instability) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • fluorouracil topical
    5ms
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=168, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    5ms
    Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=134, Not yet recruiting, Academic and Community Cancer Research United
    New P2 trial • Combination therapy
    |
    Avastin (bevacizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zynyz (retifanlimab-dlwr)
    5ms
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=168, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    5ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=226, Recruiting, BeiGene | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    6ms
    BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer (clinicaltrials.gov)
    P2/3, N=526, Not yet recruiting, Bio-Thera Solutions
    New P2/3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308
    6ms
    Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery (clinicaltrials.gov)
    P3, N=1501, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024
    Trial completion date • Surgery
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • docetaxel • pemetrexed • vinorelbine tartrate • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    6ms
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024
    Trial completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    7ms
    NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Avastin (bevacizumab) • paclitaxel • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • anetumab ravtansine (BAY 94-9343)
    7ms
    ZIABC011078: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=63, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    8ms
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    8ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=226, Recruiting, BeiGene | Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Feb 2025 --> Apr 2028
    Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    9ms
    Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab. (PubMed, Drugs R D)
    Overall, this extensive comparability exercise demonstrated BAT1706 to match EU/US-bevacizumab in terms of all physicochemical and functional attributes assessed.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Avastin (bevacizumab) • Avzivi (bevacizumab-tnjn)
    9ms
    Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=443, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jun 2024 --> May 2023
    Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    9ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Recruiting, BeiGene | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    9ms
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    10ms
    AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) (ESMO 2023)
    No new safety signals were identified in either arm. The OS data are premature and need further follow-up.
    Clinical • P2 data • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    10ms
    Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov)
    P3, N=692, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jun 2024
    Trial completion date • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    10ms
    Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov)
    P2, N=112, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    10ms
    Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    12ms
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    12ms
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Avzivi (bevacizumab-tnjn)
    1year
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    over1year
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    over1year
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1b/2, N=202, Not yet recruiting, BeiGene | Initiation date: Nov 2022 --> Feb 2023
    Trial initiation date • Combination therapy • Mismatch repair • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
    almost2years
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    2years
    AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC). (ASCO 2022)
    BAT1706 is a similar biological product to the anti-angiogenic agent bevacizumab. Secondary endpoints include duration of response, time to response, disease control rate, clinical benefit rate, and progression-free survival (all by investigator’s assessment), overall survival, safety, pharmacokinetics, and immunogenicity. Study enrollment is ongoing.
    Clinical
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)